

Supplemental Table 3.

Statistical analysis of AK lesional clearance rates at 3 months and 6 months following PDT.

A linear mixed-effects model was used to compare responses to the treatments as a function of body site, and as a function of immunological status.

The model was applied to compare lesion responses at 3, 6, 9, and 12 months after PDT treatment \pm 5FU pretreatment. Values shown in the tables are the lesion clearance rate (CR; % reduction in initial lesion counts). Analyses are stratified according to body site, or for all sites combined, with P-values indicated. Data were adjusted for body site location and baseline number of lesions. *CI*, confidence interval. Relative differences at 9 and 12 months were not statistically significant (data not shown).

At 3 months

	No 5FU [95% CI]	+ 5FU [95% CI]	P-value	Comment
Overall CR	45.9% [36.3, 55.5]	74.5% [64.9, 84.1%]	< 0.001	Adjusted for location and baseline number of lesions
<i>Subgroup analysis by location</i>				
Face	60.3% [43.7, 77.0%]	83.0% [66.4, 99.7%]	< 0.001	Adjusted for baseline number of lesions
Scalp	31.0% [22.3, 39.8%]	72.1% [63.3, 80.8%]	< 0.001	Adjusted for baseline number of lesions
Forearms	48.4% [2.8, 94.1%]	65.8% [20.2, 100%]	0.10	Adjusted for baseline number of lesions
<i>Subgroup analysis by immune status</i>				
Normal	49.5% [40.1, 58.8%]	73.4% [64.0, 82.7%]	< 0.001	Adjusted for baseline # of lesions, and for location
Organ transplant	34.6% [4.3, 64.8%]	76.7% [46.1, 100%]	< 0.001	Adjusted for baseline # of lesions, and for location

At 6 months

	No 5FU [95% CI]	+ 5FU [95% CI]	P-value	Comment
Overall CR	38.8% [25.7, 51.8]	66.9% [53.8, 80.0%]	< 0.001	Adjusted for location and baseline number of lesions
<i>Subgroup analysis by location</i>				
Face	52.3% [31.5, 73.2%]	71.6% [50.8, 92.5%]	0.07	Adjusted for baseline number of lesions
Scalp	28.1% [17.2, 39.0%]	57.2% [46.3, 68.1%]	< 0.001	Adjusted for baseline number of lesions
Forearms	33.4% [4.6, 62.2%]	77.9% [49.1, 100%]	< 0.001	Adjusted for baseline number of lesions
<i>Subgroup analysis by immune status</i>				
Normal	43.1% [29.2, 57.0%]	69.0% [55.1, 82.9%]	< 0.001	Adjusted for baseline # of lesions, and for location
Organ transplant	23.8% [0, 55.8%]	58.4% [26.3, 90.4%]	0.005	No adjustment due to small sample size